Compound of formula III: ** Formula ** or a pharmaceutically acceptable salt thereof, where X is O, S, N-CN, N-OH, or N-OR10； W is N or C； the dashed line indicates the presence or absence of a link and when the dashed line indicates the presence of a link or W is N then R4 is absent, otherwise R4 is -H, -OH, -OCF3, -halo, - (C1-C6) alkyl, - CH2OH, -CH2Cl, -CH2Br, -CH2I, -CH2F, -CH (halo) 2, -CF3, -OR10, -SR10, -COOH, -COOR10, -C (O) R10 , -C (O) H, -OC (O) R10, -OC (O) NHR10, -NHC (O) R13, -CON (R13) 2, -S (O) 2R10, or -NO2； R10 is - (C1-C4) alkyl； each R13 is independently -H, - (C1-C4) alkyl, - (C1-C4) alkenyl, - (C1-C4) alkynyl, or -phenyl； each R3 is independently: (a) -H or (C1-C6) alkyl； or (b) two R3 groups together form a bridge (C2-C6), which is unsubstituted or substituted with 1, 2 or 3 independently selected R8 groups and containing said bridge optionally -HC>； = CH- within the bridge (C2 -C6)； or (c) two R3 groups together form a bridge -CH2-N (Ra) -CH2-, a ** Formula ** bridge, or a ** Formula ** bridge； Ra is selected from -H, - (C1-C6) alkyl, - (C3-C8) cycloalkyl, -CH2-C (O) -Rc, - (CH2) -C (O) -ORc, - (CH2) - C (O) -N (Rc) 2, - (CH2) 2-O-Rc, - (CH2) 2-S (O) 2-N (Rc) 2, or - (CH2) 2-N (Rc) S (O) 2-Rc； Rb is selected from: (a) -H, - (C1-C6) alkyl, - (C3-C8) cycloalkyl, -heterocycle (3 to 7 members), -N (Rc) 2, -N (Rc) - ( C3-C8) cycloalkyl, or -N (Rc) -heterocycle (3 to 7 members)； or (b) -phenyl, -heteroaryl (5 or 6 members), -N (Rc) -phenyl, or -N (Rc) -heteroaryl (5 to 10 members), each of which is unsubstituted or substituted with 1, 2 or 3 independently selected R7 groups；Compuesto de fórmula III: **Fórmula** o una sal farmacéuticamente aceptable del mismo, donde X es O, S, N-CN, N-OH, o N-OR10； W es N o C； la línea discontinua indica la presencia o ausencia de un enlace y cuando la línea discontinua indica la presencia de un enlace o W es N entonces R4 está ausente, de lo contrario, R4 es -H, -OH, -OCF3, -halo, -(C1-C6)alquilo, - CH2OH, -CH2C
